
- Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session at $11.11. The company shares are currently trading at $10.9, down 1.89 percent in the after-hours trading session.
- TRACON Pharmaceuticals (NASDAQ:TCON) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy. TRACON shares traded in a range of $1.8 to $1.9 on a day volume of 62.85 thousand shares, closed regular trading session at $1.9. The company shares are currently trading at $1.81, down 4.74 percent in the after-hours trading session.